Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-997-2400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.09 million
Profitability
Miscellaneous
Employees152
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) released its quarterly earnings data on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.03. The specialty pharmaceutical company earned $5.77 million during the quarter, compared to analyst estimates of $5.82 million. Adamis Pharmaceuticals had a negative return on equity of 86.04% and a negative net margin of 205.32%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
5 brokers have issued 12 month target prices for Adamis Pharmaceuticals' shares. Their predictions range from $1.10 to $7.00. On average, they expect Adamis Pharmaceuticals' stock price to reach $4.53 in the next twelve months. This suggests a possible upside of 738.0% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.
What is the consensus analysts' recommendation for Adamis Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.
Has Adamis Pharmaceuticals been receiving favorable news coverage?
News stories about ADMP stock have been trending neutral on Friday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adamis Pharmaceuticals earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Adamis Pharmaceuticals.
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include PhaseBio Pharmaceuticals (PHAS), Sesen Bio (SESN), Mustang Bio (MBIO), MEI Pharma (MEIP), Kala Pharmaceuticals (KALA), Scpharmaceuticals (SCPH), OASMIA PHARMACE/ADR (OASM), Fulcrum Therapeutics (FULC), Eton Pharmaceuticals (ETON), Adamas Pharmaceuticals (ADMS), Menlo Therapeutics (MNLO), Paratek Pharmaceuticals (PRTK), Helix Biopharma (HBPCF), Strongbridge Biopharma (SBBP) and Aptinyx (APTX).
What other stocks do shareholders of Adamis Pharmaceuticals own?
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Mr. Richard C. Williams, Chairman & Consultant (Age 75)
- Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
- Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
- Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
- Mr. Robert B. Rothermel, Consultant & Director (Age 75)
Who are Adamis Pharmaceuticals' major shareholders?
Adamis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.14%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.
Which major investors are buying Adamis Pharmaceuticals stock?
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $0.54.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $33.18 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.
What is Adamis Pharmaceuticals' official website?
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
